New drug combos aim to boost survival in Hard-to-Treat cancers
NCT ID NCT03281369
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested several immunotherapy-based drug combinations in 214 people with advanced stomach, gastroesophageal junction, or esophageal cancer that could not be removed by surgery or had spread. Participants received either standard chemotherapy or chemotherapy plus the immunotherapy atezolizumab (Tecentriq) and other drugs. The goal was to see if these combinations were safe and worked better than standard treatment alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab (Tecentriq) plus chemotherapy (5-FU, leucovorin, oxaliplatin) and other immunotherapy drugs
What this could lead to
If successful, this could point toward more effective treatment combinations for advanced gastric and esophageal cancers, potentially improving survival and response rates.
What could go wrong
This is an early-phase (1b/2) umbrella study with multiple arms, so results are preliminary. The combinations may not prove better than standard chemotherapy and could have added side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barts and The London School of Medicine and Dentistry - Barts Cancer Institute (BCI)-CECM
London, 0, United Kingdom
-
Beatson West of Scotland Cancer Centre
Glasgow, G12 0YN, United Kingdom
-
Blacktown Hospital
Blacktown, New South Wales, 2148, Australia
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Hospital Universitari Vall dHebron
Barcelona, 08035, Spain
-
Korea University Anam Hospital
Seoul, 02841, South Korea
-
Mayo Clinic Cancer Center
Scottsdale, Arizona, 85259, United States
-
Monash Medical Centre-Moorabbin Campus
Clayton, Victoria, 3168, Australia
-
National Cheng Kung University Hospital
Tainan, 70457, Taiwan
-
National Taiwan University Hospital (NTUH) - Cancer Research Center
Zhongzheng Dist., 10051, Taiwan
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Rambam Health Care Campus
Haifa, 3109601, Israel
-
Samsung Medical Center
Seoul, 135-710, South Korea
-
Seoul National University Bundang Hospital
Gyeonggi-do, 13620, South Korea
-
Seoul National University Hospital (SNUH) - Medical Oncology Center
Seoul, 03080, South Korea
-
Sourasky Medical Centre
Tel Aviv, 64239, Israel
-
Taipei Veterans General Hospital
Taipei, 11217, Taiwan
-
Tennessee Oncology - Nashville
Nashville, Tennessee, 37203, United States
-
The Catholic University of Korea St. Vincent's Hospital
Suwon, 442-723, South Korea
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
The Royal Marsden
London, SW7 3RP, United Kingdom
-
The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton
Sutton, SM2 5PT, United Kingdom
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030-4000, United States
-
UCLA Jonsson Comprehensive Cancer Center
Santa Monica, California, 90404, United States
-
Uni of Southern California
Los Angeles, California, 90033, United States
-
Universidad de Navarra - Clinica Universitaria de Navarra (CUN)
Pamplona, Navarre, 31008, Spain
-
University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC)
Songpa-gu, 05505, South Korea
-
Yonsei University College of Medicine (YUCM)-Yonsei Cancer Center
Seoul, South Korea